Itraconazole (ITRA) with standard radiotherapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma multiforme (GBM) ITRA-RAD: Phase I Clinical Study

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519239-40-01

Acronym

IIT-2024/01

Enrollment

Registered

2025-03-21

Start date

2025-04-07

Completion date

Unknown

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioblastom

Brief summary

Determination of the maximum tolerated dose (MTD) of ITRA administered concomitantly with standard treatment (RT and TMZ)

Interventions

DRUGItraconazol Aristo 100 mg Hartkapseln

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Determination of the maximum tolerated dose (MTD) of ITRA administered concomitantly with standard treatment (RT and TMZ)	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026